

FOI 3572

5th February 2026

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Question 1. How many patients who have a current diagnosis of Multiple Sclerosis received treatment in the last six months with any of the following treatment regimens (July 2025 – December 2025)?

- **Ocrevus (ocrelizumab) IV (300mg/30ml)**
- **Ocrevus (ocrelizumab) Subcutaneous (920mg/23ml)**
- **Kesimpta (ofatumumab)**
- **Briumvi (ublituximab)**
- **Mavenclad (cladribine)**
- **Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic)**
- **Natalizumab (Tysabri and Tyruko)**

Response:

- **Ocrevus (ocrelizumab) IV (300mg/30ml) - 99**
- **Ocrevus (ocrelizumab) Subcutaneous (920mg/23ml) - 39**
- **Kesimpta (ofatumumab) – Not stocked**
- **Briumvi (ublituximab) - Not stocked**
- **Mavenclad (cladribine) - 0**
- **Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic) - 0**
- **Natalizumab (Tysabri and Tyruko) - 33**

Question 1a. Of the patients identified in question one, how many patients received the same treatment in the previous six-month period? (i.e. How many of the same patients received treatment with each treatment regimen in January 2025 to June 2025 AND July 2025 – December 2025?)

- **Ocrevus (ocrelizumab) IV (300mg/30ml)**

- **Ocrevus (ocrelizumab) Subcutaneous (920mg/23ml)**
- **Kesimpta (ofatumumab)**
- **Briumvi (ublituximab)**
- **Mavenclad (cladribine)**
- **Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic)**
- **Natalizumab (Tysabri and Tyruko)**

Response: This information is not held.

Question 2. How many patients have received a new diagnosis for Multiple Sclerosis in the latest six-month period (July 2025 – December 2025)?

Response: This information is not held. The Trust can only identify hospital admissions with MS.

Question 2a. Of the patients identified in question two, how many of these patients have received any of the following treatment regimens as their first treatment following their Multiple Sclerosis diagnosis?

- **Ocrevus (ocrelizumab) IV (300mg/30ml)**
- **Ocrevus (ocrelizumab) Subcutaneous (920mg/23ml)**
- **Kesimpta (ofatumumab)**
- **Briumvi (ublituximab)**
- **Mavenclad (cladribine)**
- **Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic)**
- **Natalizumab (Tysabri and Tyruko)**

Response: Please see response to Question 2 above.

Email: Foi.Team@Southerntrust.hscni.net